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Introduction
Chronic HIV infection has been associated with an
increased incidence of non AIDS-defining cancers. To
date, only a limited number of cases of bladder cancer
have been reported in association with HIV infection.
Therefore, the aim of this study was to investigate a series
of HIV-associated bladder cancer cases.
Methods
A retrospective study was performed involving HIV posi-
tive patients with concomitant bladder cancer, combining
cases from multiple institutions with published case
reports. Data were extracted regarding patient demo-
graphics (age, gender), HIV status (CD4+ cell count, HIV
viral load), clinical presentation, pathology, cancer treat-
ment, and outcome. Accrued data were analyzed using
descriptive statistics.
Results
A total of 11 patients were identified with an average age
of 53 years (range 33 to 67), most of whom were male
(M:F 9:2). Their median CD4 cell count was 280 cells/
mm3 (range 106 – 572 cells/mm3) and median HIV load
<50 copies/mL (range <50 – 665,000 copies/mL). Five
(45%) patients smoked tobacco, two had recurrent cysti-
tis, two had bladder calculi, and one patient had previous
pelvic radiation therapy for cervical cancer. Nine (82%)
presented with hematuria. Less common presentations
included lower abdominal pain, irritative urinary symp-
toms (frequency, urgency and/or dysuria), and weight
loss. Most cases (10/11) had transitional cell carcinoma
and one person had squamous cell carcinoma. At presen-
tation, two cases had stage 0a disease, five had stage I dis-
ease, and two stage IV disease. Treatment with
transurethral resection of bladder tumor (TURBT) was fol-
lowed by intravesical or systemic chemotherapy, cystec-
tomy and/or radiation. Intravesical mitomycin C or
epirubicin was used, despite the fact that BCG in one case
did not cause complications. Several patients (64%) were
alive following therapy, although many (71%) suffered
from local relapse and metastatic disease.
Conclusion
Bladder cancer should be added to the growing list of
Non-AIDS defining cancers likely to be encountered in
HIV-infected patients now living longer with controlled
HIV disease. Afflicted patients are likely to present at a
younger age and with only mild immunosuppression.
Hematuria, dysuria, frequency and/or urgency in an HIV-
infected patient warrants complete evaluation, including
a work up for bladder cancer. Although most patients pre-
sented with early stage disease, the course for their bladder
cancers was notable for frequent relapses and subsequent
metastases. HIV positive individuals should be counseled
on the potential risks (e.g., smoking) of bladder cancer.
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